Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China

Shun Lü, Qing Zhou, Xiaoqing Liu, Yingying Du, Yun Fan, Ying Cheng, Jian Fang, You Lü, Cheng Zhi Huang, Jianying Zhou, Yong Song, Kai Wang, Hongming Pan, Nong Yang, Juan Li, Gongyan Chen, Jianhua Chang, Jiuwei Cui, Zhe Liu, Chunxue Bai, Helong Zhang, Huadong Zhao, Kaiting Zhang, Gerson Peltz, Heyan Li, Yi‐Long Wu